A systematic review of metabolite profiling in gestational diabetes mellitus

Diabetologia

Volumn 57, Issue 12, 2014, Pages 2453-2464

  Huynh, Jennifer ^a   Xiong, Grace ^a   Bentley Lewis, Rhonda ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amino acids; Gestational diabetes mellitus; Metabolite profiling; Metabolites; Metabolomics; Systematic review

Indexed keywords

AMINO ACID; FATTY ACID; N(G),N(G) DIMETHYLARGININE; BIOLOGICAL MARKER;

FEMALE; HUMAN; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; METABOLISM; PREGNANCY;

BIOLOGICAL MARKERS; DIABETES, GESTATIONAL; FEMALE; HUMANS; METABOLOMICS; PREGNANCY;

EID: 84926667894     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3371-0     Document Type: Review

References (78)

1. American Diabetes Association (2014) Standards of medical care in diabetes, 2014. Diabetes Care 37 (Suppl 1): S14-S80
2. American Diabetes Association (2013) Standards of medical care in diabetes, 2013. Diabetes Care 36 (Suppl 1): S11-S66
3. Shah BR, Retnakaran R, Booth GL (2008) Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care 31: 1668-1669
4. Bentley-Lewis R (2009) Late cardiovascular consequences of gestational diabetes mellitus. Semin Reprod Med 27: 322-329
5. Bentley-Lewis R, Powe C, Ankers E, Wenger J, Ecker J, Thadhani R (2014) Effect of race/ethnicity on hypertension risk subsequent to gestational diabetes mellitus. Am J Cardiol 113: 1364-1370
6. Kelly BB, Narula J, Fuster V (2012) Recognizing global burden of cardiovascular disease and related chronic diseases. Mt Sinai J Med 79: 632-640
7. Thadhani R, Powe CE, Tjoa ML et al (2010) First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus. Diabetes Care 33: 664-669
8. Thadhani R, Wolf M, Hsu-Blatman K, Sandler L, Nathan D, Ecker JL (2003) First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. Am J Obstet Gynecol 189: 171-176
9. Smirnakis KV, Plati A, Wolf M, Thadhani R, Ecker JL (2007) Predicting gestational diabetes: choosing the optimal early serum marker. Am J Obstet Gynecol 196: 410. e411-416, discussion 410. e416-417
10. Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R (2003) First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 26: 819-824
11. Savvidou M, Nelson SM, Makgoba M, Messow CM, Sattar N, Nicolaides K (2010) First-trimester prediction of gestational diabetes mellitus: examining the potential of combining maternal characteristics and laboratory measures. Diabetes 59: 3017-3022
12. Friedrich N (2012) Metabolomics in diabetes research. J Endocrinol 215: 29-42
13. Roberts LD, Koulman A, Griffin JL (2014) Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. Lancet Diabetes Endocrinol 2: 65-75
14. Fanos V, Atzori L, Makarenko K, Melis GB, Ferrazzi E (2013) Metabolomics application in maternal-fetal medicine. Biomed Res Int 2013: 720514
15. Ho JE, Larson MG, Vasan RS et al (2013) Metabolite profiles during oral glucose challenge. Diabetes 62: 2689-2698
16. Shaham O, Wei R, Wang TJ et al (2008) Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 4: 214
17. Bentley-Lewis R, Xiong G, Lee H, Yang A, Huynh J, Kim C (2014) Metabolomic analysis reveals amino acid responses to an oral glucose tolerance test in women with prior history of gestational diabetes mellitus. J Clin Transl Endocrinol 1: 38-43
18. Lumbreras B, Porta M, Márquez S, Pollán M, Parker LA, Hernández-Aguado I (2008) QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘-omics’-based technologies. Clin Biochem 41: 1316-1325
19. Metzger BE, Phelps RL, Freinkel N, Navickas IA (1980) Effects of gestational diabetes on diurnal profiles of plasma glucose, lipids, and individual amino acids. Diabetes Care 3: 402-409
20. Butte NF, Hsu HW, Thotathuchery M, Wong WW, Khoury J, Reeds P (1999) Protein metabolism in insulin-treated gestational diabetes. Diabetes Care 22: 806-811
21. Seghieri G, Breschi MC, Anichini R et al (2003) Serum homocysteine levels are increased in women with gestational diabetes mellitus. Metabolism 52: 720-723
22. Tarim E, Bagis T, Kilicdag E et al (2004) Elevated plasma homocysteine levels in gestational diabetesmellitus. Acta Obstet Gynecol Scand 83: 543-547
23. Cetin I, de Santis MS, Taricco E et al (2005) Maternal and fetal amino acid concentrations in normal pregnancies and in pregnancies with gestational diabetes mellitus. Am J Obstet Gynecol 192: 610-617
24. Guven MA, Kilinc M, Batukan C, Ekerbicer HC, Aksu T (2006) Elevated second trimester serum homocysteine levels in women with gestational diabetes mellitus. Arch Gynecol Obstet 274: 333-337
25. Akturk M, Altinova A, Mert I et al (2010) Asymmetric dimethylarginine concentrations are elevated in women with gestational diabetes. Endocrine 38: 134-141
26. Sertkaya AC, Kafkasli A, Turkcuoglu I, Karabulut AB (2011) Asymmetric dimethylarginine level in hyperglycemic gestation. Endocrine 40: 237-242
27. Chen X, Scholl TO, Leskiw M, Savaille J, Stein TP (2010) Differences inmaternal circulating fatty acid composition and dietary fat intake in women with gestational diabetes mellitus or mild gestational hyperglycemia. Diabetes Care 33: 2049-2054
28. Sachse D, Sletner L, Mørkrid K et al (2012) Metabolic changes in urine during and after pregnancy in a large, multiethnic population-based cohort study of gestational diabetes. PLoS One 7: e52399
29. Telejko B, Zonenberg A, Kuzmicki M et al (2009) Circulating asymmetric dimethylarginine, endothelin-1 and cell adhesion molecules in women with gestational diabetes. Acta Diabetol 46: 303-308
30. Idzior-Waluś B, Cyganek K, Sztefko K et al (2008) Total plasma homocysteine correlates in women with gestational diabetes. Arch Gynecol Obstet 278: 309-313
31. Graça G, Duarte IF, Barros AS et al (2010) Impact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J Proteome Res 9: 6016-6024
32. Diaz SO, Pinto J, Graça G et al (2011) Metabolic biomarkers of prenatal disorders: an exploratory NMR metabonomics study of second trimester maternal urine and blood plasma. J Proteome Res 10: 3732-3742
33. Graça G, Goodfellow BJ, Barros AS et al (2012) UPLC-MS metabolic profiling of second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers. Mol Biosyst 8: 1243-1254
34. Diaz SO, Barros AS, Goodfellow BJ et al (2013) Second trimester maternal urine for the diagnosis of trisomy 21 and prediction of poor pregnancy outcomes. J Proteome Res 12: 2946-2957
35. Pappa KI, Vlachos G, Theodora M, Roubelaki M, Angelidou K, Antsaklis A (2007) Intermediate metabolism in association with the amino acid profile during the third trimester of normal pregnancy and diet-controlled gestational diabetes. Am J Obstet Gynecol 196: 65. e61-65
36. McCormack SE, Shaham O, McCarthy MA et al (2013) Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes 8: 52-61
37. Newgard CB, An J, Bain JR et al (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9: 311-326
38. Dejong CH, van de Poll MC, Soeters PB, Jalan R, Olde Damink SW (2007) Aromatic amino acid metabolism during liver failure. J Nutr 137: 1579S-1585S, discussion 1597S-1598S
39. Cheng S, Rhee EP, Larson MG et al (2012) Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 125: 2222-2231
40. Wang TJ, Larson MG, Vasan RS et al (2011) Metabolite profiles and the risk of developing diabetes. Nat Med 17: 448-453
41. Townsend DM, Tew KD, Tapiero H (2004) Sulfur containing amino acids and human disease. Biomed Pharmacother 58: 47-55
42. Sibal L, Agarwal SC, Home PD, Boger RH (2010) The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6: 82-90
43. Toutouzas K, Riga M, Stefanadi E, Stefanadis C (2008) Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Horm Metab Res 40: 655-659
44. Böger RH, Bode-Böger SM, Szuba A et al (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847
45. Miyazaki H, Matsuoka H, Cooke JP et al (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99: 1141-1146
46. Surdacki A, Nowicki M, Sandmann J et al (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33: 652-658
47. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62: 2425-2430
48. Abbasi F, Asagmi T, Cooke JP et al (2001) Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88: 1201-1203
49. Böger RH, Zoccali C (2003) ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 4: 23-28
50. Gumus II, Kargili A, Kaygusuz I et al (2012) The association between serum asymmetric dimethyl arginine levels and a history of gestational diabetes among healthy women. Blood Coagul Fibrinolysis 23: 391-395
51. Pleiner J, Mittermayer F, Langenberger H et al (2007) Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes. Wien Klin Wochenschr 119: 483-489
52. Mittermayer F, Mayer BX, Meyer A et al (2002) Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia 45: 1372-1378
53. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24: 1912-1919
54. Valkonen VP, Päivä H, Salonen JT et al (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128
55. Meinitzer A, Seelhorst U, Wellnitz B et al (2007) Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 53: 273-283
56. Böger RH (2005) Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 10 (Suppl 1): S19-S25
57. Bryson CL, Ioannou GN, Rulyak SJ, Critchlow C (2003) Association between gestational diabetes and pregnancy-induced hypertension. Am J Epidemiol 158: 1148-1153
58. Barden A, Singh R, Walters BN, Ritchie J, Roberman B, Beilin LJ (2004) Factors predisposing to pre-eclampsia in women with gestational diabetes. J Hypertens 22: 2371-2378
59. Paradisi G, Biaggi A, Ferrazzani S, de Carolis S, Caruso A (2002) Abnormal carbohydrate metabolism during pregnancy: association with endothelial dysfunction. Diabetes Care 25: 560-564
60. Wolfe RR (1998) Fat metabolism in exercise. Adv Exp Med Biol 441: 147-156
61. Boden G, Shulman GI (2002) Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32 (Suppl 3): 14-23
62. Boden G (2003) Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 111: 121-124
63. Fulcher GR, Catalano C, Walker M et al (1992) A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabet Med 9: 908-914
64. Vaag A, Skött P, Damsbo P, Gall MA, Richter EA, Beck-Nielsen H (1991) Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 88: 1282-1290
65. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D (2009) Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 32 (Suppl 2): S373-S377
66. Mihalik SJ, Goodpaster BH, Kelley DE et al (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18: 1695-1700
67. Mahendran Y, Vangipurapu J, Cederberg H et al (2013) Association of ketone body levels with hyperglycemia and type 2 diabetes in 9, 398 Finnish men. Diabetes 62: 3618-3626
68. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298: 299-308
69. Hoppel CL, Genuth SM (1980) Carnitine metabolism in normalweight and obese human subjects during fasting. Am J Physiol 238: E409-E415
70. Soeters MR, Sauerwein HP, Duran M et al (2009) Muscle acylcarnitines during short-term fasting in lean healthy men. Clin Sci (Lond) 116: 585-592
71. Lu J, Xie G, Jia W (2013) Metabolomics in human type 2 diabetes research. Front Med 7: 4-13
72. Catalano PM (2014) Trying to understand gestational diabetes. Diabet Med 31: 273-281
73. Catalano PM, Huston L, Amini SB, Kalhan SC (1999) Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 180: 903-916
74. Buchanan TA (2001) Pancreatic B cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86: 989-993
75. Desoye G, Hauguel-de Mouzon S (2007) The human placenta in gestational diabetes mellitus. The insulin and cytokine network. Diabetes Care 30 (Suppl 2): S120-S126
76. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE (2007) Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 30 (Suppl 2): S112-S119
77. Robitaille J, Grant AM (2008) The genetics of gestational diabetes mellitus: evidence for relationship with type 2 diabetes mellitus. Genet Med 10: 240-250
78. Ben-Haroush A, Yogev Y, Hod M (2004) Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabet Med 21: 103-113